Sign In

Klaus Schollmeier

Professional Board Member and Advisor to the Pharma/Biotech and Life Science Industry

Professional Background

Klaus Schollmeier is a distinguished figure in the Pharma and Biotech industry, leveraging his extensive experience as an advisor and board member for several biotech companies. With an illustrious career, Klaus has contributed to significant advancements in biotechnology, particularly through his leadership roles in various high-profile firms. His career journey reflects a commitment to innovation and excellence in the pharmaceutical sector, making him a vital asset to the organizations he collaborates with.

From 2013 to 2015, Mr. Schollmeier served as the Chief Executive Officer of SuppreMol, headquartered in Munich, Germany. Under his guidance, the company achieved remarkable milestones until its acquisition by Baxalta. Before his tenure at SuppreMol, Klaus held the position of Chief Executive Officer at Santhera Pharmaceuticals in Basel, Switzerland, from 2004 to 2011, where he transformed the organization, subsequently taking on the chairman's role until 2013. His strategic vision and effective leadership were pivotal during these transformative years.

His journey in the Biotech sphere began in 2003 as CEO of Graffinity Pharmaceuticals AG in Heidelberg, Germany. Here, Klaus played a critical role in merging Graffinity with MyoContract AG, subsequently laying the groundwork for the formation of Santhera Pharmaceuticals. These strategic maneuvers showcased his aptitude for mergers and acquisitions, positioning him as a leader equipped to navigate the industry's complexities.

Prior to venturing into biotechnology, Klaus honed his analytical and operational expertise within the pharmaceutical sector. He spent 16 years at BASF, Knoll, and Abbott. Among his notable roles were heading oncology and immunology research at BASF’s central laboratories in Ludwigshafen, Germany, and serving as a senior director of biotechnology at BASF Bioresearch Corporation in Cambridge, Massachusetts, from 1989 to 1993. He also held significant business roles, including general manager of BASF Pharma Netherlands and vice president/general manager for Western Europe.

Education and Achievements

Klaus Schollmeier is an alumnus of the University of Düsseldorf, Germany, where he earned his Ph.D. in biology. His pursuit of knowledge and excellence in the field has propelled him to influential academic circles, culminating in his position as an adjunct research associate professor at Boston University Medical School in Massachusetts in 1991. This academic tenure not only underscores his commitment to education and research but also reflects his deep understanding of the scientific principles that underpin biotechnology.

In addition to his considerable industry experience, Klaus has actively sought opportunities to share his expertise with emerging and established companies. His role as an external management advisor and venture team coach at Chemovator GmbH highlights his dedication to fostering growth and innovation within the biotech community. He is known for encouraging entrepreneurial spirit and facilitating the development of new ideas and products.

Current and Former Board Positions

As a testament to his distinguished career, Klaus Schollmeier currently holds several prominent board positions that reflect his influence and leadership in the biotech sector:

  • Inthera Bioscience, Zürich, Switzerland – Chairman
  • Anergis Bioscience, Lausanne, Switzerland – Chairman
  • Apceth, Munich, Germany – Board Member
  • Affiris, Vienna, Austria – Board Member
  • Ethernygen, Berlin, Germany – Board Member

Klaus's extensive board membership experience extends to numerous former positions, underscoring his leadership and pivotal contributions to these organizations:

  • Vira Therapeutics, Innsbruck, Austria – Former Chairman
  • Santhera Pharmaceuticals, Basel, Switzerland – Former Chairman
  • PCovery, Copenhagen, Denmark – Former Chairman

This extensive portfolio of leadership roles provides Klaus with deep insights into the challenges and opportunities within the biotech field, allowing him to effectively guide strategic decisions and foster corporate growth.

In conclusion, Klaus Schollmeier embodies a combination of scientific acumen and business know-how that sets him apart in the biopharmaceutical sector. His unwavering commitment to advancing the field through innovation and strategic leadership positions him as a respected figure in the Pharma/Biotech industry. His contributions continue to resonate throughout the various organizations he influences, underscoring his pivotal role in shaping the future of biotechnology and pharmaceuticals.

Related Questions

How did Klaus Schollmeier transition from the pharmaceutical industry to becoming a leader in the biotech field?
What innovative strategies did Klaus Schollmeier implement during his time at SuppreMol that led to its successful acquisition?
In what ways has Klaus Schollmeier contributed to the growth of Anergis Bioscience and other biotech firms on his board?
What insights does Klaus Schollmeier provide as an external management advisor at Chemovator GmbH?
How does Klaus Schollmeier's academic background influence his approach to leadership in the biopharmaceutical industry?
Klaus Schollmeier
Add to my network

Location

Hemsbach, Baden-Württemberg, Germany